Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Astrid S., Daugvilaite, Viktorija, De Filippo, Katia, Berg, Christian, Mavri, Masa, Benned-Jensen, Tau, Juzenaite, Goda, Hjortø, Gertrud, Rankin, Sara, Våbenø, Jon, Rosenkilde, Mette M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115334/
https://www.ncbi.nlm.nih.gov/pubmed/33980979
http://dx.doi.org/10.1038/s42003-021-02070-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115334/
https://www.ncbi.nlm.nih.gov/pubmed/33980979
http://dx.doi.org/10.1038/s42003-021-02070-9

Ejemplares similares